Back to Search
SYDNEY HETHERINGTON, DMD
DMD
Student in an Organized Health Care Education/Training Program
NPI: 1740969310Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
COMMENTARY: understanding the benefits of pediatric anti-retroviral treatment in resource-limited settings.
PMID 19057455·Pediatr Infect Dis J·2009
8-other
Primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: changing patterns of vascular access, radial versus femoral artery.
PMID 19596690·Heart·2009
4-observational
Radial artery anomaly and its influence on transradial coronary procedural outcome.
PMID 18977799·Heart·2009
4-observational
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
PMID 18332899·Pharmacogenomics J·2008
6-review
Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants.
PMID 17719934·J Pediatr·2007
2-rct
Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.
PMID 17005843·Antimicrob Agents Chemother·2006
3-trial
Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.
PMID 16870768·Antimicrob Agents Chemother·2006
3-trial
Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.
PMID 16220082·Pediatr Infect Dis J·2005
3-trial
Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants.
PMID 16189088·Antimicrob Agents Chemother·2005
8-other
Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.
PMID 15728889·Antimicrob Agents Chemother·2005
3-trial
Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP.
PMID 15514209·Arterioscler Thromb Vasc Biol·2005
8-other
Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.
PMID 15040535·Antivir Ther·2004
4-observational
Dietetic guidelines: diet in secondary prevention of cardiovascular disease (first update, June 2003).
PMID 15250843·J Hum Nutr Diet·2004
1-meta
Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction.
PMID 12869229·Int J STD AIDS·2003
8-other
Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy.
PMID 12091849·J Pediatr·2002
3-trial
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
PMID 11943262·Lancet·2002
8-other
Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
PMID 11797183·Clin Infect Dis·2002
3-trial
Understanding drug hypersensitivity: what to look for when prescribing abacavir.
PMID 11806176·AIDS Read·2001
8-other
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
PMID 11726000·Clin Ther·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 625 ELMWOOD AVE
ROCHESTER, NY 14620 - Phone
- (585) 275-5051
Quick Facts
- NPI
- 1740969310
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile